ArticleAntimicrobial agents and chemotherapy2014
A clinical adverse drug reaction prediction model for patients with chagas disease treated with benznidazole.
Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Safety Profile of Benznidazole in the Treatment of Chronic Chagas Disease: Experience of a Referral Centre and Systematic Literature Review with Meta-Analysis.Drug safety · 2018Pooled it
- Comparative bioavailability of three benznidazole formulations in healthy individuals: a randomised study.Memorias do Instituto Oswaldo Cruz · 2026Trial
- Adverse reactions to etiological treatment in patients with Chagas disease in the Western Potiguar mesoregion of Brazil: a cross-sectional study.Sao Paulo medical journal = Revista paulista de medicina · 2026Observational
- Adverse drug events in hospitalized COVID-19 patients: a pharmacovigilance perspective on ICU management and fentanyl exposure.Frontiers in epidemiology · 2026Article
- Trypanocidal Treatment for Chronic Chagas Disease: Past, Present, and Future.Revista da Sociedade Brasileira de Medicina Tropical · 2025Review
- Why Treat Chronic Forms of Chagas Disease with Benznidazole if Adverse Reactions are Very Frequent?Arquivos brasileiros de cardiologia · 2024Article
- First Report of Seropositivity toJournal of parasitology research · 2024Article
- Mixed T Helper1/T Helper2/T Cytotoxic Profile in Subjects with Chronic Chagas Disease with Hypersensitivity Reactions to Benznidazole.Microbiology spectrum · 2022Article
- Comparative Study of the Effect of Snake Venoms on the Growth of Ciliates Tetrahymena pyriformis: Identification of Venoms with High Antiprotozoal Activity.Doklady. Biochemistry and biophysics · 2022Article
- Pharmacogenomic Profile and Adverse Drug Reactions in a Prospective Therapeutic Cohort of Chagas Disease Patients Treated with Benznidazole.International journal of molecular sciences · 2021Article
- Benznidazole decreases the risk of chronic Chagas disease progression and cardiovascular events: A long-term follow up study.EClinicalMedicine · 2021Article
- Does Progressive Introduction of Benznidazole Reduce the Chance of Adverse Events in the Treatment of Chagas Disease?The American journal of tropical medicine and hygiene · 2019Article
- Hydroxymethylnitrofurazone treatment in indeterminate form of chronic Chagas disease: Reduced intensity of tissue parasitism and inflammation-A histopathological study.International journal of experimental pathology · 2018Article
- Impact of benznidazole treatment on the functional response of Trypanosoma cruzi antigen-specific CD4+CD8+ T cells in chronic Chagas disease patients.PLoS neglected tropical diseases · 2018Article
- Expanding the toolbox for Trypanosoma cruzi: A parasite line incorporating a bioluminescence-fluorescence dual reporter and streamlined CRISPR/Cas9 functionality for rapid in vivo localisation and phenotyping.PLoS neglected tropical diseases · 2018Article
- Reporting of adverse reactions to benznidazole: does medical expertise matter?Revista panamericana de salud publica = Pan American journal of public health · 2018Article
- Prediction Models for Decision-Making on Chagas Disease.Arquivos brasileiros de cardiologia · 2017Article
- Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease.PloS one · 2017Article
- Safety Profile of Nifurtimox and Treatment Interruption for Chronic Chagas Disease in Colombian Adults.The American journal of tropical medicine and hygiene · 2015Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Benznidazole (BZN) is the main trypanocidal drug used to treat Chagas disease, and the evidence supporting the benefits of BZN use during the chronic phase of the disease will favor its use in millions of individuals. However, more than 30% of patients treated with BZN may suffer adverse drug reactions (ADRs), and the development of tools to identify those patients at risk is highly desirable. In the present study, we aimed to identify predictive factors for ADRs in Chagas disease patients treated with BZN. Among 195 patients included in the study, 48.7% experienced ADRs and 31.3% had ADRs that caused BZN treatment discontinuation. Overall ADRs and ADRs that caused BZN treatment discontinuation were more common among women and in those who graduated from elementary school. Overall ADRs were also less frequent among black individuals. Based on logistic regression analysis, female sex (odds ratio [OR], 2.9; 95% confidence interval [CI], 1.5 to 5.4), graduation from elementary school (OR, 2.0; 95% CI, 1.1 to 3.8), and white (OR, 5.0; 95% CI, 1.0 to 24.1) and mulatto (OR, 5.6; 95% CI, 1.1 to 28.7) races were considered to predict overall ADRs, and female sex (OR, 2.3; 95% CI, 1.2 to 4.3) was considered to predict ADRs that caused BZN treatment discontinuation. Graduation from elementary school also presented a tendency to predict ADRs that caused BZN treatment discontinuation (OR, 1.8; 95% CI, 0.9 to 3.6). The logistic regression (LR) models to predict ADRs to BZN described in this study may become important tools to minimize ADRs and improve patients' compliance and thus assist physicians treating patients with Chagas disease with BZN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.